WO1999065525A1 - Agents permettant d'abaisser la tension oculaire et derives d'ester phosphorique - Google Patents
Agents permettant d'abaisser la tension oculaire et derives d'ester phosphorique Download PDFInfo
- Publication number
- WO1999065525A1 WO1999065525A1 PCT/JP1999/003277 JP9903277W WO9965525A1 WO 1999065525 A1 WO1999065525 A1 WO 1999065525A1 JP 9903277 W JP9903277 W JP 9903277W WO 9965525 A1 WO9965525 A1 WO 9965525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- intraocular pressure
- vasopressin
- benzoyl
- agent
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title abstract description 41
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims abstract description 69
- 229960003726 vasopressin Drugs 0.000 claims abstract description 66
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims abstract description 65
- 108010004977 Vasopressins Proteins 0.000 claims abstract description 65
- 102000002852 Vasopressins Human genes 0.000 claims abstract description 65
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 161
- 230000004410 intraocular pressure Effects 0.000 claims description 105
- -1 Cetylaminopropoxy Chemical group 0.000 claims description 78
- 239000003795 chemical substances by application Substances 0.000 claims description 75
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 63
- 230000003042 antagnostic effect Effects 0.000 claims description 34
- 238000001990 intravenous administration Methods 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000003889 eye drop Substances 0.000 claims description 21
- 208000010412 Glaucoma Diseases 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 206010030043 Ocular hypertension Diseases 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 3
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract description 41
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract description 41
- 230000002265 prevention Effects 0.000 abstract description 11
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 abstract description 9
- 230000008485 antagonism Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 51
- 230000000694 effects Effects 0.000 description 48
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 47
- 238000012360 testing method Methods 0.000 description 45
- 239000000243 solution Substances 0.000 description 44
- 238000000034 method Methods 0.000 description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 36
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 22
- 239000000843 powder Substances 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 15
- UACMTQPSUBFZOR-FTJBHMTQSA-N n-[4-[(2s,3ar)-2-hydroxy-2,3,3a,4-tetrahydro-1h-pyrrolo[1,2-a]quinoxaline-5-carbonyl]phenyl]-2-(4-methylphenyl)benzamide Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1C(=O)NC1=CC=C(C(=O)N2C3=CC=CC=C3N3C[C@@H](O)C[C@@H]3C2)C=C1 UACMTQPSUBFZOR-FTJBHMTQSA-N 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 229940012356 eye drops Drugs 0.000 description 14
- KSNUCNRMDYJBKT-UHFFFAOYSA-N n-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide Chemical compound C1=CC(OCCCNC(=O)C)=CC=C1C(=O)N1CCC(N2C3=CC=CC=C3CCC2=O)CC1 KSNUCNRMDYJBKT-UHFFFAOYSA-N 0.000 description 14
- 239000002504 physiological saline solution Substances 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000002689 soil Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000002997 ophthalmic solution Substances 0.000 description 12
- 229940054534 ophthalmic solution Drugs 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229940044551 receptor antagonist Drugs 0.000 description 10
- 239000002464 receptor antagonist Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000000865 phosphorylative effect Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000010976 amide bond formation reaction Methods 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- CDSBFDCCJJDFCV-CKZSCMLPSA-N chembl2107777 Chemical compound C([C@H]1CC[C@@]2(C(=O)N(C3=CC=C(C=C32)OCC)S(=O)(=O)C=2C(=CC(=CC=2)C(=O)NC(C)(C)C)OC)CC1)CN1CCOCC1 CDSBFDCCJJDFCV-CKZSCMLPSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001882 diuretic effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- WRNXUQJJCIZICJ-UHFFFAOYSA-N mozavaptan Chemical compound C12=CC=CC=C2C(N(C)C)CCCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C WRNXUQJJCIZICJ-UHFFFAOYSA-N 0.000 description 6
- 229950000546 mozavaptan Drugs 0.000 description 6
- 230000004493 normal intraocular pressure Effects 0.000 description 6
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 206010067013 Normal tension glaucoma Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- PMMYEEVYMWASQN-QWWZWVQMSA-N cis-4-hydroxy-D-proline Chemical compound O[C@H]1C[NH2+][C@@H](C([O-])=O)C1 PMMYEEVYMWASQN-QWWZWVQMSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 201000002978 low tension glaucoma Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000003287 ciliary artery Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- SGECHWQKWQJBAO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphoryl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(=O)(N(C(C)C)C(C)C)OCC1=CC=CC=C1 SGECHWQKWQJBAO-UHFFFAOYSA-N 0.000 description 3
- 210000003733 optic disk Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 229940127325 Vasopressin V2 Receptor Antagonists Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000002686 anti-diuretic effect Effects 0.000 description 2
- 229940124572 antihypotensive agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 2
- 229960000966 dipivefrine Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 239000002536 vasopressin receptor antagonist Substances 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- ZCNVMFKSWODSRV-XCBNKYQSSA-N (2s,4r)-4-hydroxy-1-(2-nitrophenyl)pyrrolidine-2-carboxylic acid Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C1=CC=CC=C1[N+]([O-])=O ZCNVMFKSWODSRV-XCBNKYQSSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IONYGGJUUJFXJK-UHFFFAOYSA-N 2,3,4,5,6-pentachlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IONYGGJUUJFXJK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OFHNVKGAGGVKNF-UHFFFAOYSA-N C(C1=CC=CC=C1)P(O)(O)O Chemical compound C(C1=CC=CC=C1)P(O)(O)O OFHNVKGAGGVKNF-UHFFFAOYSA-N 0.000 description 1
- MEGJMKFSJYUVIB-UHFFFAOYSA-N C(C1=CC=CC=C1)[ClH]P(=O)(Cl)[ClH]CC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)[ClH]P(=O)(Cl)[ClH]CC1=CC=CC=C1 MEGJMKFSJYUVIB-UHFFFAOYSA-N 0.000 description 1
- ZSIAANIILFGLQH-UHFFFAOYSA-N C1(=CC=CC=C1)[ClH]P(=O)(Cl)[ClH]C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)[ClH]P(=O)(Cl)[ClH]C1=CC=CC=C1 ZSIAANIILFGLQH-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- DULCUDSUACXJJC-UHFFFAOYSA-N Ethyl phenylacetate Chemical compound CCOC(=O)CC1=CC=CC=C1 DULCUDSUACXJJC-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- YIINTZRQVLYONJ-UHFFFAOYSA-N O1CCN(CC1)[ClH]P(=O)(Cl)[ClH]N1CCOCC1 Chemical compound O1CCN(CC1)[ClH]P(=O)(Cl)[ClH]N1CCOCC1 YIINTZRQVLYONJ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000891463 Tetraedron Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- IRJKSAIGIYODAN-ISLYRVAYSA-N benzyl (ne)-n-phenylmethoxycarbonyliminocarbamate Chemical compound C=1C=CC=CC=1COC(=O)/N=N/C(=O)OCC1=CC=CC=C1 IRJKSAIGIYODAN-ISLYRVAYSA-N 0.000 description 1
- IYTZBDDDAQHMBE-UHFFFAOYSA-N bis(4-nitrophenoxy)phosphoryl bis(4-nitrophenyl) phosphate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OP(=O)(OP(=O)(OC=1C=CC(=CC=1)[N+]([O-])=O)OC=1C=CC(=CC=1)[N+]([O-])=O)OC1=CC=C([N+]([O-])=O)C=C1 IYTZBDDDAQHMBE-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- IQTILSQVDUNLNB-UHFFFAOYSA-N chloro(methoxy)phosphinic acid Chemical compound COP(O)(Cl)=O IQTILSQVDUNLNB-UHFFFAOYSA-N 0.000 description 1
- XGRJZXREYAXTGV-UHFFFAOYSA-N chlorodiphenylphosphine Chemical compound C=1C=CC=CC=1P(Cl)C1=CC=CC=C1 XGRJZXREYAXTGV-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UCDHYFZYUGDETN-UHFFFAOYSA-N cyanophosphonic acid Chemical compound OP(O)(=O)C#N UCDHYFZYUGDETN-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- JMQGGPRJQOQKRT-UHFFFAOYSA-N diphenyl hydrogen phosphate;azide Chemical compound [N-]=[N+]=[N-].C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 JMQGGPRJQOQKRT-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- ZKEIYKMRUDYLSA-NSHDSACASA-N methyl (2s)-1-(2-nitrophenyl)pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1C1=CC=CC=C1[N+]([O-])=O ZKEIYKMRUDYLSA-NSHDSACASA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- JAOLNXGJDXODBO-UHFFFAOYSA-N phosphepane Chemical compound C1CCCPCC1 JAOLNXGJDXODBO-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- GFCRHEYQICBSHB-UHFFFAOYSA-N quinoxalin-2-yl dihydrogen phosphate Chemical compound OP(O)(=O)Oc1cnc2ccccc2n1 GFCRHEYQICBSHB-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- RFZXFOYQOFYOKR-UHFFFAOYSA-N triquinolin-8-yl phosphate Chemical compound C1=CN=C2C(OP(OC=3C4=NC=CC=C4C=CC=3)(OC=3C4=NC=CC=C4C=CC=3)=O)=CC=CC2=C1 RFZXFOYQOFYOKR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Definitions
- the present invention relates to an intraocular pressure lowering agent to be applied to treatment and prevention of glaucoma and ocular hypertension.
- the present invention further relates to a novel phosphate derivative.
- Glaucoma is a disease caused by sustained or repeated rises in intraocular pressure (intraocular pressure) beyond the normal range, causing organic damage to the eyes and visual impairments such as abnormal visual fields. .
- Ocular hypertension is a disease in which intraocular pressure is higher than normal, but does not impair visual function, and may develop into glaucoma after a long course.
- the goal of pharmacotherapy for glaucoma and ocular hypertension is to reduce and maintain intraocular pressure to a healthy level without visual impairment by intraocular pressure-lowering drugs.
- a carbonic anhydrase inhibitor oral, ophthalmic solution
- hypertonic osmotic agent injection
- pilocarpine ophthalmic solution
- epinephrine and its prodrug dipivefrin
- 3 receptor blocker Ophthalmic solution
- isopropyl unoprostone Ophthalmic solution
- taking a carbonic anhydrase inhibitor may cause gastrointestinal disorders, urolithiasis, and electrolyte abnormalities.
- epinephrine and dipivefrin are also limited to open-angle glaucoma, as well as rebound hyperemia due to vasoconstriction, eye pain, bradycardia, mydriasis, and systemic heart rate May cause an increase in number and blood pressure.
- Eye drops containing 3 receptor blockers as active ingredients have side effects such as headache and depressive symptoms in the central nervous system, asthma-like symptoms in the respiratory system, bradycardia and hypotension in the circulatory system. It has been reported to occur (Pharmaceutical Journal, 28, 705, 1992). Isopropyl unoprostone eye drops have a high incidence of corneal epithelial damage as a side effect.
- vasopressin receptor antagonists have been used to treat heart failure, edema such as cerebral edema, ascites, pulmonary edema, arginine vasopressin hypersecretion syndrome, renal failure, hepatitis, hypertension, cirrhosis, hyponatremia, hypokalemia It has been developed for the treatment of diabetes and circulatory insufficiency and diuretics (JP-A-7-2800, JP-A-3-173870, JP-A-4-321669, JP-A-4-154765).
- vasopressin On intraocular pressure, the intravenous administration of desmopressin (a vasopressin analog) (Ivnest. Oph tha lmol. Vis. Sci., 29, 406-410, 1988) It has an intraocular pressure increasing effect, as reported in the third ventricular administration of vasopressin (Invest. Ophthalmol. Vis. Sc, 25, 932-937, 1984) It has been reported. On the other hand, continuous infusion of isotonic vasopressin into the anterior chamber suppressed intraocular pressure elevation (Exp. Eye Res., 65, 517–531, 1997), and intravenous vasopressin was significantly reduced. It has also been reported to have an intraocular pressure-lowering effect, such as lowering intraocular pressure (Neuropeptide, 29, 193-203, 1995).
- vasopressin V1 receptor was converted to human retinal pigment epithelial cultured cells (Curr. Eye Res., 10, 81 1 -816 , 1991) Dinus excision It is reported to be present in the short posterior ciliary artery (J. Vase. Res., 34, 464-472, 1997).
- vasopressin receptors are distributed in ocular tissues.However, it has been reported that vasopressin has an opposing effect of increasing or decreasing intraocular pressure. The physiological significance is unknown at all.
- the present invention provides a novel intraocular pressure lowering agent having an excellent intraocular pressure lowering effect and having few side effects for application to treatment and prevention or prevention of glaucoma and ocular hypertension.
- the purpose is to do so.
- a first aspect of the present invention is an intraocular pressure-lowering agent comprising a compound having a vasopressin V1 receptor antagonistic activity or a pharmacologically acceptable salt thereof as an active ingredient.
- a second aspect of the present invention is an ester phosphate derivative represented by the following general formula (1).
- R 1 represents hydrogen or alkyl having 1 to 4 carbon atoms
- M 1 and M 2 may be the same or different, and may be hydrogen or a monovalent pharmacologically acceptable alkyl.
- a first aspect of the present invention is an intraocular pressure-lowering agent comprising a compound having a vasopressin V1 receptor antagonistic activity or a pharmacologically acceptable salt thereof as an active ingredient.
- Vasopressin is a peptide hormone consisting of nine amino acids, which binds to its receptor to exert antidiuretic and vasopressor effects.
- Vasopressin receptors are broadly classified into two types: cyclic AMP-independent V1 receptors and cyclic AMP-dependent V2 receptors. It has been clarified that the expression of the antidiuretic effect of vasopressin is mediated through the V2 receptor in the renal collecting duct, and the expression of the vasopressor effect is mediated by the V1 receptor in vascular smooth muscle.
- the compound having vasopressin V1 receptor antagonistic activity means not only a compound having selective antagonistic activity on vasopressin V1 receptor, but also a compound having vasopressin V1 and V2 receptors. A compound having an antagonistic action is also meant.
- the compound having a vasopressin V1 receptor antagonistic effect used in the present invention is not particularly limited as long as it has a vasopressin V1 receptor antagonistic effect.
- a vasopressin V1 receptor antagonistic effect for example, 1- ⁇ 1-[4- (3-A Cetylaminopropoxy) benzoyl] —4-piperidyl ⁇ -3,4-dihydro-12 (1H) —quinolinone (hereinafter OPC-21268), SR49059,
- compound (1) A compound represented by the following general formula (1) (hereinafter, referred to as compound (1));
- R 1 represents hydrogen or alkyl having 1 to 4 carbon atoms
- ⁇ 1 and ⁇ 2 may be the same or different, and are hydrogen or monovalent pharmacologically acceptable.
- a compound represented by the following general formula ( ⁇ ) (hereinafter, referred to as compound ( ⁇ ));
- R 1 represents hydrogen or alkyl having 1 to 4 carbon atoms
- R 1 represents hydrogen or alkyl having 1 to 4 carbon atoms.
- the alkyl having 1 to 4 carbon atoms is not particularly restricted but includes, for example, methyl, ethyl, propyl, butyl and the like, and these may be branched or linear. Of these, methyl is preferred.
- R 1 may be in any of the ortho, meta and para positions.
- M 1 and M 2 may be the same or different and represent hydrogen or a monovalent pharmacologically acceptable alkali metal salt.
- the monovalent pharmacologically acceptable alkali metal salt is not particularly limited, and examples thereof include a sodium salt, a potassium salt, and a lithium salt. Of these, sodium salts and potassium salts are preferred.
- the above compound (1) is generally more water-soluble in salt form than in free form. Therefore, when used for pharmaceutical applications, it is preferable to select a compound in the form of a salt according to the application.
- Examples of the compound (1) include the following compounds.
- the above compound (A), that is, 4 '-[(2-methyl-1,4,5,6-tetrahydroimidazo [4,5-d] [1] benzazepine-6-yl) carbonyl]- 2-Fenylpenzanilide hydrochloride has been used as a therapeutic agent for congestive heart failure, a therapeutic agent for renal disease and a diuretic (Journa 1 of Pharmacology and Experimental Therapeutics, 282 (1 ), 301-308, 1997; Eur. J. Pharmacol., 3_2_2 (2), 225-230, 1997).
- the inventors of the present invention show that the above compound (A) exerts an intraocular pressure lowering action which cannot be predicted from the above-mentioned known drug effects, and is expected ophthalmic diseases such as glaucoma, ocular hypertension, and normal tension glaucoma. Was found to be suitable as a therapeutic agent.
- the above compound (A) can be produced, for example, using the method described in Example 18 of International Publication WO95 / 03305.
- the compound (B) is a biphenyl derivative represented by the general formula (B).
- R 1 represents hydrogen or alkyl having 1 to 4 carbons.
- the alkyl having 1 to 4 carbon atoms is not particularly restricted but includes, for example, methyl, ethyl, propyl, butyl and the like, and these may be branched or linear. Of these, methyl is preferred.
- R 1 may be in any of the ortho, meta and para positions.
- R 1 is in the para-position and is methyl (2S, 3aR) _2-hydroxy-5_ [4 — [[2 -— (para-tolyl Benzoyl] amino] benzoyl] 1-1,2,3,3a, 4,5-hexahydropyro [1,2-a] quinoxaline (hereinafter referred to as VP-343) and R 1 are in the ortho position, Methyl (2 S, 3 aR) — 2-hydroxy-5- [4 — [[2- (orthotolyl) benzoyl] amino] benzoyl] — 1,2,3,3a, 4,5-hexahydropyrro Mouth [1,2-a] Quinoxaline (hereinafter referred to as VP-386) is preferred.
- VP-343 is known to have a diuretic effect
- the inventors of the present invention show that VP-343 exerts an intraocular pressure lowering effect that cannot be predicted from the above-mentioned known medicinal effects, causing glaucoma and ocular hypertension. It has been found that the composition is suitable as a therapeutic agent for ophthalmic diseases such as bariasis and normal tension glaucoma.
- VP— 386 is a new compound where R 1 is in the ortho position and is methyl It has the structural features described above. VP-386 has an ability to bind to vasopressin V1 receptor and has vasopressin V1 receptor antagonism. Based on these properties, VP-386 exhibits an excellent intraocular pressure lowering effect and is suitable as a therapeutic agent for expected ophthalmic diseases such as glaucoma, ocular hypertension, and normal tension glaucoma.
- OPC—2 1 2 6 8 (Hy pertention, 23, 2 17-2 2 2, 1 994) is a selective vasopressin V 1 receptor antagonist, and SR49 059 is a selective vasopressin Is a VI receptor antagonist, and the compound (A) (YM087; J. Pharma col. Ex p. Ther., 282, 311-308, 199 7)
- Vasopressin VI and V 2 receptor antagonist, VP- 343 is a vasopressin V 1 and V 2 receptor antagonist, [] 3 _mercapto—) 3, ⁇ -eyelome thylenepropionyl 1 , O— Me— Ty r 2 , A rg 8 ] — vasopressin (V 2 255; J. Med. Chem., 23, 364, 1980) is a peptide-selective vasopressin V 1 receptor antagonist Agent.
- the compound having vasopressin V1 receptor antagonism used in the intraocular pressure-lowering agent of the present invention is a basic compound
- its pharmacologically acceptable salt includes, for example, hydrochloride, sulfate And inorganic or organic salts such as nitrate, phosphate, hydrobromide, tartrate, acetate, citrate, fumarate, maleate and oxalate.
- the compound having vasopressin V 1 receptor antagonistic activity used in the intraocular pressure lowering agent of the present invention is an acidic compound
- examples of the pharmacologically acceptable salt thereof include a sodium salt, a potassium salt, Calcium salt, lithium salt, and magnesium salt can be exemplified.
- vasopressin receptors have been reported to be distributed in ocular tissues.However, it has been reported that vasopressin has an opposing effect of increasing or decreasing intraocular pressure. Physiological significance is unknown at all, and it is very difficult to predict from a known drug effect that a compound having the above-mentioned vasopressin V1 receptor antagonistic activity has an excellent intraocular pressure lowering effect.
- the compound having a vasopressin VI receptor antagonistic action exerts an excellent intraocular pressure lowering action and has extremely few side effects. Therefore, an intraocular pressure-lowering agent can be obtained by using a compound having vasopressin VI receptor antagonistic activity as an active ingredient, which is suitable as a therapeutic and / or prophylactic agent for glaucoma and ocular hypertension. Therefore, the intraocular pressure lowering agent containing the compound having vasopressin V1 receptor antagonistic activity of the present invention as an active ingredient can be used as a glaucoma treatment agent, a glaucoma prevention agent, a treatment agent for ocular hypertension, and a prevention agent for ocular hypertension.
- the intraocular pressure lowering agent of the present invention also includes a glaucoma treatment agent, a glaucoma prevention agent, an ocular hypertension treatment agent, and an ocular hypertension prevention agent.
- the intraocular pressure lowering agent of the present invention can also be used as a therapeutic or preventive agent for normotensive glaucoma exhibiting a condition in which intraocular pressure does not increase.
- the dose of the compound having vasopressin V1 receptor antagonism used in the intraocular pressure lowering agent of the present invention is determined in consideration of the patient's condition such as age, body weight, etc., administration route, disease symptoms and severity, etc. Can be set as appropriate.
- the amount of the active ingredient of the intraocular pressure-lowering agent of the present invention for an adult is preferably 0.1 to 100 mg Z per day, more preferably 1 to 100 mg Z human. 660 O mg Z human.
- the active ingredient concentration of the intraocular pressure-lowering agent of the present invention for an adult is preferably 0.001 to 10% (V / W), More preferably, it is 0.01-2% (V / W).
- the amount of the active ingredient of the intraocular pressure lowering agent of the present invention for an adult is preferably 5 to 150 Omg Z per day, more preferably 10 to 300 mg / human. mg Z human.
- the intraocular pressure-lowering agent of the present invention is produced by mixing a compound having vasopressin V1 receptor antagonistic activity or a pharmacologically acceptable salt thereof with a conventional pharmaceutical carrier and preparing an appropriate dosage form.
- a compound having vasopressin V1 receptor antagonistic activity or a pharmacologically acceptable salt thereof with a conventional pharmaceutical carrier and preparing an appropriate dosage form.
- the compound having vasopressin V1 receptor antagonism is added to the pharmaceutical composition as it is, Alternatively, it is preferably contained in a pharmaceutically acceptable nontoxic and inert carrier, and the content is preferably 0.1 to 99.5% by weight, more preferably. Or 0.5 to 90% by weight.
- the carrier examples include solid, semi-solid, or liquid diluents, fillers, and other prescription auxiliaries, which may be used alone or in combination of two or more. Good.
- the intraocular pressure lowering agent of the present invention is preferably administered in a dosage unit form.
- the administration method of the intraocular pressure-lowering agent of the present invention is not particularly limited, and examples thereof include local administration such as tissue administration, intravenous administration, ophthalmic administration, and nasal administration, oral administration, and rectal administration. Can be mentioned.
- the dosage form of the intraocular pressure lowering agent of the present invention is not particularly limited.
- a dosage form suitable for the above-mentioned administration method can be appropriately selected.
- the intraocular pressure lowering agent of the present invention may be administered in a tissue or intravenously using a liquid dosage unit form such as a solution or suspension for subcutaneous, intramuscular or intravenous injection.
- a non-toxic salt or salt solution may be added to make the injection liquid isotonic.
- the above-mentioned liquid preparation or suspension suspends or dissolves a certain amount of the compound having vasopressin VI receptor antagonistic activity in a non-toxic liquid carrier such as an aqueous or oily medium suitable for injection, and then suspends the solution. It can be manufactured by sterilizing a suspension or solution.
- the above liquid preparation or suspension may be produced by placing a certain amount of a compound having vasopressin V1 receptor antagonistic activity in a vial, and then sterilizing and sealing the vial and its contents.
- a preliminary vial or carrier is prepared. Is also good.
- the intraocular pressure-lowering agent of the present invention When the intraocular pressure-lowering agent of the present invention is administered by eye, forms such as eye drops and eye ointments can be used.
- the eye drops may contain a stabilizer, a preservative and the like.
- the pH of the above-mentioned eye drops is not particularly limited as long as it is within the range permitted by ophthalmic preparations.
- the intraocular pressure-lowering agent of the present invention When used as an eye drop or an ointment, its usage and dosage are It is selected according to the patient's condition, age, etc., but in the case of eye drops, it is usually preferable to apply 1 to 5 drops per time, 2 to 4 times a day, and in the case of eye ointments It is usually preferable to apply an appropriate amount to the conjunctival sac once to three times a day.
- examples of the dosage form include powders, powders, tablets, dragees, capsules, granules, suspensions, solutions, syrups, drops, Solid or liquid dosage units, such as sublingual tablets and other dosage forms, may be mentioned.
- the above powder is produced by appropriately reducing a compound having vasopressin V1 receptor antagonistic activity.
- the above powder is prepared by appropriately reducing a compound having vasopressin V1 receptor antagonistic activity to a fine powder, and then mixing with a pharmaceutical carrier such as edible carbohydrates such as starch and mannitol, and other additives. Can be manufactured.
- the tablets can be made by preparing a powder mixture, granulating or slugging, then adding a disintegrant or lubricant and tableting.
- the above powder mixture is obtained by mixing a powdered compound having vasopressin VI receptor antagonistic activity with the above diluent or base, and if necessary, a binder, a dissolution retarder, a reabsorbent, An adsorbent or the like may be used in combination.
- the powder mixture can be granulated by first moistening with a binder and then forcing through a sieve. Further, the powder mixture may be granulated by crushing the imperfect slag obtained after applying the powder mixture to a tableting machine.
- the granules thus produced can be prevented from sticking to each other by adding a lubricant.
- the lubricated mixture may then be tableted, and the resulting uncoated tablet may be coated with a film or coated with sugar.
- the intraocular pressure reducing agent of the present invention may be directly tableted after mixing with a fluid inert carrier without going through the steps of granulation and slag formation as described above.
- the intraocular pressure lowering agent of the present invention may be provided with a transparent or translucent protective coating composed of a sealing film of Sierrac, a coating of sugar or a polymer material, and a polishing coating composed of wax. .
- the above capsules are manufactured by filling powdered powder and powder or granulated powder and powder into a capsule made of gelatin such as gelatin. Can be.
- a disintegrant or a solubilizer to the above capsules can improve the efficacy of the medicine when the capsules are taken.
- a fine powder of a compound having a vasopressin VI receptor antagonistic action may be suspended and dispersed in vegetable oil, polyethylene glycol, glycerin, a surfactant or the like, and this may be wrapped in a gelatin sheet to form a soft capsule.
- the intraocular pressure-lowering agent of the present invention can be in another oral administration form such as a solution, syrup, elixir, suspension and the like, and the dosage unit is such that a certain amount contains a certain amount of the drug. It can be in the form.
- the syrup can be produced by dissolving a compound having vasopressin VI receptor antagonistic activity in an appropriate aqueous flavor solution, and the elixir can be produced by using a nontoxic alcoholic carrier. it can.
- the suspension can be formulated by dispersing a compound having vasopressin V1 receptor antagonistic activity in a non-toxic carrier.
- the dosage unit formulation for oral administration of the intraocular pressure-lowering agent of the present invention may be, if necessary, encapsulated in a mouth or encapsulated in a polymer, wax or the like. As a result, the action time of the intraocular pressure lowering agent of the present invention can be extended and sustained release can be achieved.
- a suppository in which a compound having vasopressin V1 receptor antagonistic activity is mixed with a water-soluble or insoluble low-melting-point solid carrier and a mixture thereof is used. Can be used.
- the lubricant and fluidizing agent are not particularly limited, and include, for example, colloidal silicic acid, talc, stearic acid, magnesium stearate, stearic acid salts such as calcium stearate, solid polyethylene glycol, mineral oil, etc. Can be listed. These may be used alone or in combination of two or more.
- the disintegrant and solubilizer are not particularly limited, and include, for example, carboxymethylcellulose, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxystarch sodium, calcium carbonate, sodium carbonate, ethoxylation Isostearyl alcohols, polyoxyethylene sorbitol esters, and the like.
- the binder is not particularly limited, and examples thereof include syrup, starch paste, arabic gum, sodium carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, gelatin, polyvinylpyrrolidone, and polyvinyl alcohol. These may be used alone or in combination of two or more.
- the dissolution retardant is not particularly limited, and examples thereof include paraffin, wax, and hydrogenated castor oil. These may be used alone or in combination of two or more.
- the reabsorbent is not particularly limited, and examples thereof include quaternary salts. These may be used alone or in combination of two or more.
- the adsorbent is not particularly restricted but includes, for example, bentonite, kaolin, dicalcium phosphate and the like. These may be used alone or in combination of two or more.
- the emulsifier is not particularly limited, and examples thereof include polyoxyethylene sorbitol esters. These may be used alone or in combination of two or more.
- the flavor enhancer is not particularly limited, and includes, for example, pamint oil and saccharin. These may be used alone or two or more of them may be used in combination.
- the stabilizer include isotonic agents such as sodium chloride and concentrated glycerin; buffering agents such as sodium phosphate and sodium acetate; Examples thereof include nonionic surfactants such as polyoxyethylene sorbitan monoolate, polyoxyl stearate 40, and polyoxyethylene hydrogenated castor oil, sodium citrate, and sodium edetate. These may be used alone or in combination of two or more.
- the preservative include benzalkonium chloride and paraben. These may be used alone or in combination of two or more.
- the carrier is not particularly limited, and examples thereof include higher esters such as polyethylene glycol, cocoa butter, and myristyl palmitate. These may be used alone or in combination of two or more.
- a method of applying the above-mentioned intraocular pressure-lowering agent of the present invention to an animal including a human for the purpose of treatment and / or prevention and treating (treating) the same is also one of the present invention. It is also possible to use the compound having vasopressin V1 receptor antagonistic activity for industrial production (Manu facturng) of the above-mentioned intraocular pressure lowering agent of the present invention.
- the intraocular pressure lowering agent, the therapeutic agent for glaucoma, and the therapeutic agent for ocular hypertension of the present invention are all drugs containing a compound having vasopressin V1 receptor antagonistic activity as an active ingredient. As long as it contains a compound having a receptor antagonism, it is within the scope of the present invention regardless of whether or not it contains other components.
- the intraocular pressure lowering agent, the therapeutic agent for glaucoma, and the therapeutic agent for ocular hypertension of the present invention can be administered as a pharmaceutical composition to animals including humans, the pharmaceutical composition for reducing intraocular pressure, the therapeutic agent for glaucoma, respectively. It can be referred to as a pharmaceutical composition or a pharmaceutical composition for treating ocular hypertension.
- a second aspect of the present invention is an ester phosphate derivative represented by the following general formula (1).
- R 1 represents hydrogen or alkyl having 1 to 4 carbon atoms
- M 1 and M 2 may be the same or different
- R 1 , M 1 and M 2 are as described in the first present invention.
- the compound exemplified in the first present invention Can be mentioned.
- the compound (1) of the present invention is a compound represented by the above formula (B), Is characterized by being phosphorylated. That is, the phosphorylated esterified compound (1) of the present invention has improved water solubility as compared with the compound (B), and can be suitably used particularly for liquids such as eye drops and intravenous drugs. .
- the compound (B) has a solubility in water (25 ° C.) of about 4 / z gZmL and is a very poorly water-soluble compound.
- a commonly used surfactant such as tween 80, HCO60 or polyoxyl stearate 40 is used.
- the compound (1) of the present invention has a solubility of 10% or more in physiological saline, it can be used in an extremely high concentration range as compared with VP-343. Further, according to the compound (1) of the present invention, a liquid preparation can be prepared without using an extra component such as a surfactant which is irrelevant to the manifestation of the action of the liquid. Obtainable.
- the degree or duration of the intraocular pressure lowering effect when a solution (concentration: 3.7%) prepared by dissolving the compound (1) of the present invention in physiological saline is extremely excellent.
- the liquid preparation using (1) is extremely useful as a therapeutic agent for glaucoma and ocular hypertension.
- the compound (1) of the present invention can be synthesized by various methods. The typical production method is illustrated below.
- R 1 , M 1 and M 2 are as described above, and Bn represents benzyl.
- reaction formula 1 is a method for producing the phosphoric ester (1) of the present invention by phosphorylation and deprotection of the synthetic intermediate (2).
- the above synthetic intermediate (2) was converted to 1H-tetrazo-one.
- the reaction is oxidized with metabenzo-perbenzoic acid to obtain the phosphoric acid triester (3).
- N, N-diisopropyldibenzylphosphoramidite can be prepared by a known method, that is, the method of E, Uh 1 mann et al. [Tetrahedron Letters, 1023- 1026 ( 1986)] and the method of Tanaka et al. [Tetrahedron Letters, 199-202 (1986)].
- the phosphate ester (3) of the present invention can be produced by deprotecting the phosphate triester (3) by hydrogenolysis.
- other phosphating agents for example, phosphepane [Watanabe et al., Tetraedron Letters, 255-256 (1990)], N, N-getyldibenzylphosphoramidite [J. W.
- the compound (1) of the present invention can also be produced by a known method of directly phosphorylating the synthetic intermediate (2).
- Known methods for direct phosphorylation include, for example, a method using an acid chloride-type phosphorylating agent as a phosphorylating agent, a method using an acid anhydride-type phosphorylating agent as a phosphorylating agent, and imidoylphosphoric acid as an intermediate.
- phosphorylating agents such as phosphoric acid trisalt, tris (8-quinolyl) phosphoric acid, 2- (N, N-dimethylamino) -144-trophenylphosphoric acid, and phosphonimoxide for And other methods.
- Examples of the acid chloride-type phosphorylating agent include phosphorus oxychloride, phenylphosphoric acid dichloride, diphenylphosphoric acid chloride, dibenzylphosphoric acid chloride, p-nitrophenylphosphoric acid dichloride, dimorpholinophosphoric acid chloride, bis (/ 3, ⁇ ,) 3-trichloroethyl chloride) phosphoric acid chloride, ⁇ -diphenyl- ⁇ , monomorpholinopyrophosphoric acid chloride and the like.
- Examples of the acid anhydride-type phosphorylating agent include: benzylphosphorous acid, diphenylphosphoric anhydride, tetra (paranitrophenyl) pyrophosphoric acid, tetrachloropyrophosphoric acid, and diphenylphosphoric acid anhydride And the like.
- imidoylphosphoric acid examples include, for example, compounds obtained from / 3-cyanoethylphosphoric acid and dicyclohexylcarposimide.
- the protecting group may be removed depending on the phosphorylating agent used. This can also be performed by a known method such as hydrolysis with an acid or alkali and catalytic reduction.
- R 1 is as described above.
- the method represented by [Reaction formula 2] is a method for producing the above-mentioned synthetic intermediate (2) from the above-mentioned amine compound (4) and the above-mentioned carboxylic acid (5) using a usual amide bond formation reaction. .
- the amide bond formation reaction can be easily performed using known amide bond formation reaction conditions.
- Examples of the known amide bond forming reaction include (i) an acid chloride method, (mouth) a carbodiimide method, (8) an activated ester method, and (2) other methods.
- the acid chloride method is a method in which a halogenating agent is reacted with the carboxylic acid (5) to form an acid chloride, which is then reacted with the amine compound (4).
- the halogenating agent include thionyl chloride, oxalyl chloride, phosphorus pentachloride and the like.
- the carpoimide method is a method in which the carboxylic acid (5) is reacted with the amine derivative (4) in the presence of a condensing agent.
- a condensing agent include dihexyl carbyl imide, N-ethyl-N '-(3-dimethylaminopropyl) carbodiimide, and carbonyldiimidazole.
- the activated ester method is a method in which the carboxylic acid (5) is converted into an activated ester, and the carboxylic acid (5) is reacted with the amine (4).
- the activated ester include nitro- or halogen-substituted phenyl esters, aromatic thioesters, N-hydroxysuccinates, 1-hydroxybenzotriazole esters, phenolic esters and the like.
- condensing agent for the phosphorus compound examples include, for example, triphenylphosphine, diphenylphosphine chloride, phenyl-1-N-phenylphosphoramide chloride, methylchlorophosphate, getyl cyanophosphate, azide diphenylphosphate, bis ( 2 -oxo-3 -oxazolidinyl) phosphinic chloride and the like.
- the method of reacting the above-mentioned amine compound (4) with the above-mentioned carboxylic acid (5) using an acid chloride method is preferred in that the compound (1) of the present invention can be obtained easily and easily.
- the solvent used for the amide bond formation reaction varies depending on the method selected.
- the solvent include halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform; aromatic hydrocarbons such as benzene, toluene, and xylene; Jetlje Ethers such as mono-ter, tetrahydrofuran, dioxane and dimethoxyethane; esters such as ethyl acetate; single solvents such as aprotic polar solvents such as N, N'-dimethylformamide, dimethylsulfoxide and hexamethylphosphoric acid triamide; Or a mixed solvent thereof.
- the carboxylic acid (5) When the carboxylic acid (5) is used in excess or the reaction is carried out in the presence of an organic base in the above amide bond formation reaction, it may be advantageous in that the reaction proceeds smoothly.
- the organic base include N-methylmorpholine, trimethylamine, triethylamine, ⁇ , ⁇ ′-dimethylamine, pyridine, 1,5-diazabicyclo [4,3,0] nonene-5 (DBN), 1, Examples thereof include 8-diazabicyclo [5,4,0] indene-7 (DBU) and 1,4-diazabicyclo [2,2,2] octane (DABCO).
- the reaction temperature of the amide bond formation reaction is preferably about 120 to 150 ° C, more preferably about 15 to 50.
- the reaction time of the amide bond formation reaction is preferably about 5 minutes to 18 hours, and more preferably about 5 minutes to 2 hours.
- the above-mentioned synthesis intermediate (2) can be obtained by performing the amide bond formation reaction and then removing the protecting group.
- the protecting group include protecting groups described in “Greene” and “Wuts”, ⁇ Protective Group Organic Synthesis (2nd edition) ”. It can be appropriately used depending on the reaction conditions.
- aprotic polar solvent examples include N, N-dimethylformamide, dimethylsulfoxide, and hexamethylphosphoric triamide.
- azodicarboxylic diesters examples include, for example, ethyl azodicarboxylate, diisopropyl azodicarboxylic acid, and dibenzyl azodicarboxylate.
- the above-mentioned amine compound (4) which is a starting material of the above [Reaction formula 2], is obtained from Magid Abou—Gharbia, Meier E. Freedeta 1., J. Med. Chem., 2_7_, 1743 (1984) ) And U.S. Pat. No. 4,446,323, as starting materials, 1-fluoro-2-nitrobenzene and trans-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, or their alkyl esters and their hydrochloric acid.
- the reaction product obtained by each of the above production methods is isolated and purified as a free compound, a salt thereof, a hydrate or various solvates.
- the salt can be produced by subjecting the salt to a usual salt formation reaction.
- Isolation and purification can be performed using ordinary chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of chromatography.
- the compound (1) of the present invention includes racemates, optically active isomers, and diastereomers. May exist alone or as a mixture.
- the racemate can be converted into an optically pure isomer by a general racemic resolution method such as a method of optically resolving a diastereomer salt with a general optically active acid (tartaric acid or the like).
- the mixture of diastereomers can be separated by a conventional method such as fractional crystallization or chromatography.
- the compound (1) of the present invention is a novel compound, and the indication of the pharmaceutical composition containing the compound (1) of the present invention as an active ingredient is not particularly limited. Examples thereof include ocular hypertension and glaucoma. it can.
- the compound (1) of the present invention also has a diuretic effect, and a pharmaceutical composition containing the compound (1) of the present invention as an active ingredient can be used as a diuretic. Therefore, a pharmaceutical composition comprising the compound (1) of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier is also one of the present invention.
- the intraocular pressure-lowering agent characterized in that a compound having a vasopressin V1 receptor antagonistic activity of the present invention or a pharmacologically acceptable salt thereof is used as an active ingredient, has an effect of improving the circulation of the optic papilla. It is also extremely useful as a novel therapeutic or prophylactic agent for glaucoma.
- Test example 1 Intraocular pressure lowering effect
- the effect of intraocular pressure lowering by intravenous administration was studied using a heron.
- the compounds (VP-383, VP-384, VP-385) obtained in Examples 2 to 4 were dissolved in physiological saline to a concentration of 15 mgZmL to prepare an intravenous preparation.
- Example 2 Male white rabbits with normal intraocular pressure (weighing 2.7-3.4 kg) were grouped into 6 birds, and the compounds obtained in Examples 2-4 were intravenously administered to give SmgZkg. The intraocular pressure lowering effect of the intravenously administered drug was examined. In the same manner as in Example 1, intraocular pressure was measured before intravenous administration and up to 4 hours after intravenous administration. The negative control was compared with the intravenous injection of the present invention using a solvent.
- test results are shown in Tables 2 to 4. *, ** and *** indicate p ⁇ 0.05, p ⁇ 0.01 and ⁇ 0.001, respectively (vs. control group), which were analyzed in the same manner as in Example 1.
- the groups administered with the compounds obtained in Examples 2 to 4 showed a significant intraocular pressure lowering effect as compared with the control group.
- the above compound (A) was dissolved in a 0.5% 11 ⁇ 060 solution to a concentration of 0.3% to prepare a test ophthalmic solution.
- Example 2 A group of 6 to 12 male white rabbits with normal intraocular pressure (body weight: 2-3 kg), and instilled 50 L of test ophthalmic solution or control solution (ophthalmic solution containing no compound (A)) on the left eye Then, the intraocular pressure lowering effect of the eye drops of the present invention was examined. In the same manner as in Example 1, Intraocular pressure was measured before and up to 4 hours after instillation. As a negative control, a solvent was used and compared with the ophthalmic solution of the present invention.
- Table 5 shows the test results (difference from intraocular pressure before administration). * Indicates ⁇ ⁇ 0.05 (vs. control group), and these were analyzed by the Student's t-test (Stude ⁇ stte st). The test ophthalmic solution-administered group showed a significant intraocular pressure lowering effect 3 hours after instillation as compared to the control group. Table 5 Intraocular pressure lowering effect of compound (A) by eye drops
- Compound (A) was dissolved in N, N-dimethylformamide to a concentration of 15 mgZmL to prepare an intravenous formulation.
- Example 2 Male white rabbits with normal intraocular pressure (weighing 2.7-3.4 kg) were grouped into groups of 5-6, using the compound (A) described above before intravenous administration and in the same manner as in Example 2. Intraocular pressure was measured up to 6 hours after intravenous administration. As a negative control, a solvent was used and compared with the intravenous injection of the present invention.
- Table 6 shows the test results (difference from intraocular pressure before administration). In addition, ** and *** indicate P 0.01 and ⁇ 0.001 (solvent group), respectively, and these were analyzed in the same manner as in Example 1.
- the compound (A) administration group showed a significant intraocular pressure lowering effect 1 to 4 hours after intravenous administration as compared to the control group.
- Table 6 Intraocular pressure-lowering effect of intravenous administration of compound (A)
- Test example 7 Intraocular pressure lowering effect
- OPC-21268 and VP-343 having vasopressin VI receptor antagonistic activity OPC-31260 and SR-121463A which are selective vasopressin V2 receptor antagonists were used.
- OPC-21268, VP-343 and SR_121463 ⁇ are 50mgZmL, 15mgZmL and 15m respectively in 100% dimethylformamide The concentration was adjusted to gZmL, and PC-31260 was adjusted to 3.lmg / mL with physiological saline.
- OPC-21268 and VP-343 having vasopressin VI receptor antagonistic activity showed a significant intraocular pressure lowering effect after intravenous administration as compared with the control group.
- OPC-31260 and SR-121463A no significant difference from the control group was observed at any time after intravenous administration.
- Test example 8 Intraocular pressure lowering effect
- a peptidic selective vasopressin V 1 receptor antagonist [One me rcapto- ⁇ ,] 3- eyel ome t hy lenepropio ny l 1, ⁇ one Me -Ty r 2, A rg 8 ] -vasopressin ( hereinafter peptidic A selective vasopressin V1 receptor antagonist, Sigma, V2255, J. Med. Chem., 2_3, 364, 1980) was dissolved in physiological saline to a concentration of 1 g / mL. Adjusted intravenous dosage.
- Example 1 Male white rabbits with normal intraocular pressure (weight 2.2-3.4 kg) 5-9 birds per group, 1 l / ⁇ gZkg of peptide-selective vasopressin V 1 receptor antagonist vein After intravenous administration, the intraocular pressure was measured in the same manner as in Example 1. As a negative control, a solvent was used and compared with the intravenous injection of the present invention.
- Table 11 shows the test results (differences from intraocular pressure before administration). * And ** indicate p ⁇ 0.05 and p ⁇ 0.01, respectively (vs. control group), which were analyzed in the same manner as in Example 1.
- the peptide-selective vasopressin V1 receptor antagonist administration group having vasopressin V1 receptor antagonistic activity showed a significant intraocular pressure lowering effect after intravenous administration as compared to the control group.
- Table 11 1 Peptide-selective vasopressin VI receptors
- Test example 9 Vasopressin receptor binding test
- Sprague-Dawley The kidneys removed from female rats were minced, homogenized with 5 OmM Tris-HCl pH 7.4, and then 50,000 Xg at 4 For 20 minutes. A 10-fold amount of buffer was added to the obtained sediment, and the mixture was centrifuged again under the same conditions and washed. Further, a buffer solution was added to the obtained sediment to prepare a rat kidney crude membrane fraction so that the protein amount became 10 mg / mL.
- test compounds Male SPF rats with S pra gu e-Dawley (body weight 240-320 g (8 weeks old) were subjected to the experiment in groups of 6 or more. After fasting for 16 to 20 hours, and acclimated for 1 hour in the metabolic cage, a solution of the test compound dissolved in physiological saline was intravenously administered at a dose of 3 mgZ kg. Immediately after administration of the test compound, a physiological saline solution (25 mL / kg) was orally loaded. Thereafter, the rats were returned to the metabolic cage, urine collected from immediately after the administration of the test compound for 4 hours, and the urine volume was measured. Physiological saline was used as a control. The test compounds were VP-382, the compound obtained in Example 1, VP-383, the compound obtained in Example 2, VP-384, the compound obtained in Example 3, and The compound VP-385 obtained in Example 4 and the compound VP-387 obtained in Example 5 were used.
- Hydroxypropyl methyl cell mouth 2910 4.
- Omg Polyethylene Dalicol 6000 0.5 mg Titanium oxide 0.5 mg
- the resulting granules were dried, passed through a 24-mesh sieve, then added with 2.5 g of magnesium stearate, and then rotary-tableted (Kikusui Seisakusho) 6. ⁇
- a tablet of 10 Omg per tablet was prepared using an X5R mortar.
- Example 4 A total of 300 mg VP-382 produced in Example 1 was powdered, and 10 g of the powder was added with 390 g of crystalline cellulose, 116 g of lactose, 50 g of low-substituted hydroxypropylcellulose, and 30 g of polyvinylpyrrolidone. Then, 12 OmL of ethanol was added, mixed uniformly, and granulated. The granulated mixture was dried at 50 ⁇ for 12 to 16 hours, passed through a 25-mesh sieve, and 4 g of magnesium stearate was added and mixed uniformly. Filled to Omg to give a hard capsule containing 5 mg per capsule. Formulation Example 4 Eye drops
- Polyethylene glycol 4000 20 Polyethylene glycol 4000 20.
- a total volume of about 2,5 L of distilled water for injection was heated to about 60 ° C, and 5.2 g of concentrated glycerin, 20 g of polyethylene glycol 4000, and 10 g of 10% lactic acid were added. Add and dissolve enough
- Hard capsules were obtained in the same manner as in Formulation Example 3, using a total of 300 mg of Compound (A) c Formulation Example 8 Eye drops
- OPC-21268 3. Omg concentrated glycerin 5.2 mg polyethylene glycol 4000 20. Omg 10% lactic acid 2. Omg water for injection
- OPC— 21268 5.
- OPC-21268 5.
- Cis-4-Hydroxy-D-proline hydrochloride (J. Org. Chem., ⁇ _, 2954, 1981) 15. Suspension of 53 g in 180 mL of methanol, cooling to 20 and thionyl chloride 21. 7 mL was added dropwise over 1 hour, and then stirred at room temperature for 1.5 hours. After concentrating the reaction solution, ether was added to the obtained residue, and the precipitated crystals were collected by filtration, washed with ether, and dried to give 15.35 g (yield: 91.3%) of the title compound.
- reaction solution was washed sequentially with water, 1N-sodium carbonate aqueous solution, 1N-hydrochloric acid, and water, and dried over anhydrous magnesium sulfate.
- the residue was subjected to silica gel column chromatography, and eluted with methanol Z chromatography (199). The eluate was concentrated, and the residue was recrystallized from ethyl acetate-hexane to obtain 1.17 g (yield: 55.0%) of the title compound.
- reaction solution was cooled to ⁇ 40, and 6 mL of a dichloromethane solution of perchlorobenzoic acid (0.646 g, 3.75 mM) was added without exceeding 0, followed by stirring at 0 for 45 minutes.
- the extract was washed successively with 10% sodium thiosulfate (20 mL ⁇ 2), a saturated aqueous solution of sodium bicarbonate and water, and dried. After evaporating to dryness under reduced pressure, the residue was applied to a silica gel column chromatography and eluted with ethyl benzeneacetate (6-4) to obtain 1.1 g (yield 72%) of the title compound as a pale yellow foam.
- the intraocular pressure lowering agent of the present invention has the above-mentioned structure, and is characterized by containing, as an active ingredient, a compound having a vasopressin V1 receptor antagonistic action or a pharmacologically acceptable salt thereof, and has no side effects. It has an excellent intraocular pressure lowering effect, and can be used as a glaucoma application agent and an ocular hypertension application agent for the treatment and prevention or prevention of glaucoma and ocular hypertension.
- the compound (1) of the present invention has the above-mentioned novel chemical structure and is a novel compound not described in any literature.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41689/99A AU4168999A (en) | 1998-06-19 | 1999-06-18 | Ocular tension lowering agents and phosphoric ester derivatives |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18806298A JP2002179694A (ja) | 1998-06-19 | 1998-06-19 | リン酸エステル誘導体及び医薬組成物 |
JP18805898A JP2002179573A (ja) | 1998-06-19 | 1998-06-19 | 緑内障治療剤及び高眼圧症治療剤 |
JP10/188062 | 1998-06-19 | ||
JP10/188058 | 1998-06-19 | ||
JP09689299A JP2002179591A (ja) | 1999-04-02 | 1999-04-02 | 眼圧下降剤 |
JP11/096892 | 1999-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999065525A1 true WO1999065525A1 (fr) | 1999-12-23 |
Family
ID=27308241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/003277 WO1999065525A1 (fr) | 1998-06-19 | 1999-06-18 | Agents permettant d'abaisser la tension oculaire et derives d'ester phosphorique |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4168999A (ja) |
WO (1) | WO1999065525A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054698A1 (en) * | 2000-01-26 | 2001-08-02 | Warner-Lambert Company | Method for preventing or treating postoperative ileus |
US6903091B2 (en) | 2001-04-12 | 2005-06-07 | Wyeth | Biphenyl vasopressin agonists |
US7053083B2 (en) | 2001-04-12 | 2006-05-30 | Wyeth | Cyclohexylphenyl vasopressin agonists |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0636608A1 (fr) * | 1993-07-30 | 1995-02-01 | Sanofi | Dérivés du 1-benzènesulfonyl-1,3-dihydro-indol-2-one, leur préparation, les compositions pharmaceutiques en contenant |
WO1995018105A1 (fr) * | 1993-12-24 | 1995-07-06 | Sanofi | Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine |
EP0694536A1 (fr) * | 1994-07-05 | 1996-01-31 | Sanofi | Dérivés de 1-benzyl-1,3-dihydro-2H-benzimidazol-2-one, leur préparation, et compositions pharmaceutiques les contenant |
EP0709386A1 (en) * | 1993-07-21 | 1996-05-01 | Yamanouchi Pharmaceutical Co. Ltd. | Fused benzazepine derivative and pharmaceutical composition containing the same |
WO1998043976A1 (fr) * | 1997-03-31 | 1998-10-08 | Wakamoto Pharmaceutical Co., Ltd. | Derives de biphenyle et compositions medicinales |
-
1999
- 1999-06-18 WO PCT/JP1999/003277 patent/WO1999065525A1/ja active Application Filing
- 1999-06-18 AU AU41689/99A patent/AU4168999A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0709386A1 (en) * | 1993-07-21 | 1996-05-01 | Yamanouchi Pharmaceutical Co. Ltd. | Fused benzazepine derivative and pharmaceutical composition containing the same |
EP0636608A1 (fr) * | 1993-07-30 | 1995-02-01 | Sanofi | Dérivés du 1-benzènesulfonyl-1,3-dihydro-indol-2-one, leur préparation, les compositions pharmaceutiques en contenant |
WO1995018105A1 (fr) * | 1993-12-24 | 1995-07-06 | Sanofi | Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine |
EP0694536A1 (fr) * | 1994-07-05 | 1996-01-31 | Sanofi | Dérivés de 1-benzyl-1,3-dihydro-2H-benzimidazol-2-one, leur préparation, et compositions pharmaceutiques les contenant |
WO1998043976A1 (fr) * | 1997-03-31 | 1998-10-08 | Wakamoto Pharmaceutical Co., Ltd. | Derives de biphenyle et compositions medicinales |
Non-Patent Citations (2)
Title |
---|
KRUSZYNSKI M. et al., "Antivasopressor Antagonists of Arginine-vasopressin", J. MED. CHEM., April 1980, Vol. 23, No. 4, pages 364-368. * |
OHTAKE Y. et al., "Novel Vasopressor V2 Receptor-selective Antagonist", BIOORG. MED. CHEM., June 1999, Vol. 7, No. 6, pages 1247-1254. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054698A1 (en) * | 2000-01-26 | 2001-08-02 | Warner-Lambert Company | Method for preventing or treating postoperative ileus |
US6645959B1 (en) | 2000-01-26 | 2003-11-11 | Warner-Lambert Company | Method for treating postoperative ileus |
US6903091B2 (en) | 2001-04-12 | 2005-06-07 | Wyeth | Biphenyl vasopressin agonists |
US7053083B2 (en) | 2001-04-12 | 2006-05-30 | Wyeth | Cyclohexylphenyl vasopressin agonists |
US7223752B2 (en) | 2001-04-12 | 2007-05-29 | Wyeth | Biphenyl vasopressin agonists |
US7329653B2 (en) | 2001-04-12 | 2008-02-12 | Wyeth | Cyclohexylphenyl vasopressin agonists |
US7465722B2 (en) | 2001-04-12 | 2008-12-16 | Wyeth | Biphenyl vasopressin agonists |
Also Published As
Publication number | Publication date |
---|---|
AU4168999A (en) | 2000-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0667156B1 (en) | Ophthalmic composition containing a 1,5-benzoxathiepine derivative for treating glaucoma | |
KR100263414B1 (ko) | 티에노 [3,2-b] 피리딘 유도체 | |
SG184832A1 (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
FR2613934A1 (fr) | Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament | |
SK3898A3 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
TWI865738B (zh) | 治療apol-1依賴性局灶性節段性腎小球硬化之方法 | |
US5290781A (en) | Ketaneserinol as an agent to reduce intraocular pressure | |
TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
TWI250873B (en) | Ophthalmic compositions for treating ocular hypertension | |
US20210179577A1 (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
JP2003327532A (ja) | ペプチダーゼ阻害剤 | |
CN115175681A (zh) | sGC活化剂用于治疗眼科疾病的用途 | |
EP2968207A1 (en) | Histone deacetylase inhibitors and compositions | |
MXPA00003390A (es) | Derivado de tiazolbenzoimidazol novedoso. | |
US5834482A (en) | Heterocyclic chemistry | |
JP2002053577A (ja) | 新規n−トリアゾリルメチル−ピペラジン誘導体、その製造方法および中間生成物、および前記誘導体を含有する医薬品 | |
WO1999065525A1 (fr) | Agents permettant d'abaisser la tension oculaire et derives d'ester phosphorique | |
WO1998043976A1 (fr) | Derives de biphenyle et compositions medicinales | |
WO2006088080A1 (ja) | シクロヘプタ[b]ピリジン-3-カルボニルグアニジン誘導体およびそれを含有する医薬品 | |
JP2002179694A (ja) | リン酸エステル誘導体及び医薬組成物 | |
JP3958391B2 (ja) | 眼疾患用薬剤 | |
FI114155B (fi) | Migreenin hoitoon käytettävä indolijohdannainen | |
JP3748697B2 (ja) | 糖尿病合併症予防薬又は治療薬 | |
JPH09508917A (ja) | フェニルピロール誘導体およびそのドーパミンd▲下3▼アンタゴニストとしての使用 | |
JP4397875B2 (ja) | 糖尿病合併症予防薬又は治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 2000554403 Format of ref document f/p: F |